Knockdown of YAP1 inhibits the proliferation of osteosarcoma cells in vitro and in vivo

Yang,Zhi; Zhang,Ming; Xu,Ke; Liu,Lin; Hou,Wei-Kun; Cai,Yuan-Zhen; Xu,Peng; Yao,Jian-Feng

doi:10.3892/or.2014.3305

Knockdown of YAP1 inhibits the proliferation of osteosarcoma cells in vitro and in vivo

Authors:
- Zhi Yang
- Ming Zhang
- Ke Xu
- Lin Liu
- Wei-Kun Hou
- Yuan-Zhen Cai
- Peng Xu
- Jian-Feng Yao
View Affiliations

Affiliations: Department of Joint Surgery, Hong Hui Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi 710054, P.R. China, Department of Internal Medicine, Hong Hui Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi 710054, P.R. China
Published online on: July 3, 2014 https://doi.org/10.3892/or.2014.3305
Pages: 1265-1272

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Yes-associated protein 1 (YAP1) is a candidate oncogene that is involved in tumorigenesis and progression of many malignant tumors. Recently, many studies have revealed that YAP1 is highly expressed in human osteosarcoma. To investigate the role of YAP1 in osteosarcoma tumorigenesis, the expression of YAP1 in the osteosarcoma cell lines (MG-63 and HOS) was knocked down by small hairpin RNA (shRNA), and the cell proliferation and colony formation assay showed that knockdown of YAP1 significantly suppressed the cell proliferation and colony formation of osteosarcoma cells. Subsequently, cell cycle distribution was analyzed by flow cytometry, and the results showed an accumulation of YAP1-knockdown cells in the G0/G1 phase, suggesting that YAP1 knockdown results in the arrest of cell cycle progression. Additionally, the knockdown of YAP1 also inhibited the tumorsphere formation in vitro and the growth of xenograft tumors in vivo. Therefore, these data suggest that YAP1 knockdown inhibits the proliferation of osteosarcoma cells. However, the mechanism of action was unclear. Further investigation showed that in the YAP1-knockdown MG-63 and HOS cells, the level of cylinD1 and c-myc expression, target genes of the Wnt signaling pathway and TOP-Flash reporter activity were all significantly decreased, which indicated that the inhibitory effect of YAP1 knockdown on osteosarcoma might be associated with the Wnt signaling pathway. Taken together, our results demonstrated that YAP1 is an important regulator of osteosarcoma tumorigenesis and knockdown of YAP1 would be a novel therapeutic strategy for osteosarcoma.

View Figures

View References

1	Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F and Terenziani M: Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol. 23:3742–3751. 2005. View Article : Google Scholar : PubMed/NCBI
2	Buddingh EP, Anninga JK, Versteegh MI, et al: Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer. 54:216–221. 2010.PubMed/NCBI
3	Federman N, Bernthal N, Eilber FC and Tap WD: The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 10:82–93. 2009. View Article : Google Scholar
4	Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 99:112–128. 2007. View Article : Google Scholar
5	Lau AN, Curtis SJ, Fillmore CM, et al: Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33:468–481. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chen W, Wang W, Zhu B, et al: A functional variant rs1820453 in YAP1 and breast cancer risk in Chinese population. PLoS One. 8:e790562013. View Article : Google Scholar : PubMed/NCBI
7	Xu MZ, Yao TJ, Lee NP, et al: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
8	Orr BA, Bai H, Odia Y, Jain D, Anders RA and Eberhart CG: Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol. 70:568–577. 2011. View Article : Google Scholar : PubMed/NCBI
9	Rosenbluh J, Nijhawan D, Cox AG, et al: β-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
10	Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273. 2006. View Article : Google Scholar : PubMed/NCBI
11	Tapon N, Harvey KF, Bell DW, et al: salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 110:467–478. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lai ZC, Wei X, Shimizu T, et al: Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 120:675–685. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sudol M: Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI
14	Fernandez-L A and Kenney AM: The Hippo in the room: a new look at a key pathway in cell growth and transformation. Cell Cycle. 9:2292–2299. 2010. View Article : Google Scholar : PubMed/NCBI
15	Xu MZ, Yao TJ, Lee NP, et al: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
16	Liu JY, Li YH, Lin HX, et al: Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
17	Camargo FD, Gokhale S, Johnnidis JB, et al: YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
18	Gilgenkrantz H: The world according to YAP: a continuous cross-talk between Wnt and Hippo pathways. Med Sci. 29:868–874. 2013.(In French).
19	Clevers H: Wnt/β-catenin signaling in development and disease. Cell. 127:469–480. 2006.
20	Wend P, Holland JD, Ziebold U and Birchmeier W: Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol. 21:855–863. 2010. View Article : Google Scholar : PubMed/NCBI
21	McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X and Hoang BH: The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kansara M, Tsang M, Kodjabachian L, et al: Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 119:837–851. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang YH, Li B, Shen L, Shen Y and Chen XD: The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int J Immunopathol Pharmacol. 26:157–167. 2013.PubMed/NCBI
24	Chan LH, Wang W, Yeung W, Deng Y, Yuan P and Mak KK: Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. Oct 21–2013.(Epub ahead of print).
25	Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273. 2006. View Article : Google Scholar : PubMed/NCBI
26	Zhao B, Wei X, Li W, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
27	Zhang X, George J, Deb S, et al: The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X: Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
29	Liu JY, Li YH, Lin HX, et al: Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
30	Kim JM, Kang DW, Long LZ, et al: Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. Hum Pathol. 42:315–323. 2011. View Article : Google Scholar : PubMed/NCBI
31	Martins-Neves SR, Lopes AO, do Carmo A, et al: Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer. 12:1392012. View Article : Google Scholar : PubMed/NCBI
32	Chang CJ, Yang JY, Xia W, et al: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100. 2011.PubMed/NCBI
33	Cordenonsi M, Zanconato F, Azzolin L, et al: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 147:759–772. 2011. View Article : Google Scholar : PubMed/NCBI
34	Zhou D, Zhang Y, Wu H, et al: Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA. 108:E1312–E1320. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ota M and Sasaki H: Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development. 135:4059–4069. 2008. View Article : Google Scholar : PubMed/NCBI
36	Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 287:11730–11739. 2012.
37	Burgess AW, Faux MC, Layton MJ and Ramsay RG: Wnt signaling and colon tumorigenesis - a view from the periphery. Exp Cell Res. 317:2748–2758. 2011. View Article : Google Scholar : PubMed/NCBI
38	McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X and Hoang BH: The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011. View Article : Google Scholar : PubMed/NCBI